NCT06816030

A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009)

An Open-label Study to Characterize the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of MK-4482 in Chinese Healthy Male Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: Male
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The goal of the study is to learn what happens to MK-4482 after single and multiple doses in healthy Chinese participants over time. Researchers also want to learn about the safety of MK-4482, including how well people tolerate it.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	MK-4482	Participants in period 1 received, MK-4482 800 mg single oral dose in the morning on Day 1. Participants in period 2 received, MK-4482 800mg oral dose administered every 12 hours (Q12H) on Day 1 through Day 6 for11 doses.

Timeline

• Start date: 2023-06-28
• Primary completion: 2023-08-05
• Completion: 2023-08-05
• First posted: 2025-02-10
• Last updated: 2026-04-16

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study